0001662579-24-000017.txt : 20240215 0001662579-24-000017.hdr.sgml : 20240215 20240215170514 ACCESSION NUMBER: 0001662579-24-000017 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240213 FILED AS OF DATE: 20240215 DATE AS OF CHANGE: 20240215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Schick Kelly CENTRAL INDEX KEY: 0001797388 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39567 FILM NUMBER: 24644723 MAIL ADDRESS: STREET 1: C/O AMAG PHARMACEUTICALS, INC. STREET 2: 1100 WINTER STREET CITY: WALTHAM STATE: MA ZIP: 02451 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: C4 Therapeutics, Inc. CENTRAL INDEX KEY: 0001662579 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 475617627 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: (617) 231-0700 MAIL ADDRESS: STREET 1: 490 ARSENAL WAY STREET 2: SUITE 120 CITY: WATERTOWN STATE: MA ZIP: 02472 4 1 wk-form4_1708034697.xml FORM 4 X0508 4 2024-02-13 0 0001662579 C4 Therapeutics, Inc. CCCC 0001797388 Schick Kelly C/O C4 THERAPEUTICS, INC. 490 ARSENAL WAY #120 WATERTOWN MA 02472 0 1 0 0 Chief People Officer 0 Common Stock 2024-02-13 4 F 0 1735 6.53 D 24951 D Common Stock 2024-02-14 4 A 0 27300 0 A 52251 D Stock Option (Right to Buy) 7.31 2024-02-14 4 A 0 122800 0 A 2034-02-13 Common Stock 122800 122800 D Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") and does not represent a sale by the Reporting Person. Represents RSUs. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following the grant date, with the first installment vesting on February 14, 2025. The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. /s/ Jolie M. Siegel, Attorney-in-Fact 2024-02-15